8-K: Oscar Health Q3 Loss Widens, Reaffirms 2025 Guidance

Oscar Health reported a wider net loss in Q3 2025 despite revenue growth and increased membership, while reaffirming its full-year 2025 financial guidance and executing a convertible notes exchange.

Summary

• Total revenue for the third quarter of 2025 increased to approximately $3.0 billion, up from $2.4 billion in Q3 2024, driven by higher membership.
• The company reported a net loss attributable to Oscar Health, Inc. of $137.5 million, or $(0.53) per diluted share, for Q3 2025, compared to a net loss of $54.6 million, or $(0.22) per diluted share, for Q3 2024.
• Loss from operations widened to $129.3 million in Q3 2025 from $48.4 million in Q3 2024, primarily due to an increase in average market morbidity resulting in a $130 million increase in the net risk adjustment transfer accrual.
• Adjusted EBITDA loss increased to $101.5 million in Q3 2025 from $11.6 million in Q3 2024.
• The medical loss ratio (MLR) increased to 88.5% in Q3 2025 from 84.6% in Q3 2024.
• The SG&A expense ratio improved to 17.5% in Q3 2025 from 19.0% in Q3 2024, attributed to greater fixed cost leverage, lower exchange fee rates, and disciplined cost management.
• Total membership grew significantly to 2,116,904 as of September 30, 2025, compared to 1,654,284 as of September 30, 2024.
• Oscar Health reaffirmed its full-year 2025 outlook, projecting total revenue between $12.0 billion and $12.2 billion, MLR between 86.0% and 87.0%, SG&A expense ratio between 17.1% and 17.6%, and loss from operations between $(300) million and $(200) million.
• On November 3, 2025, the company entered into an Exchange Agreement with Dragoneer, allowing for the exchange of up to $250 million of 7.25% convertible senior notes due 2031.
• On November 5, 2025, $187.5 million aggregate principal amount of these notes were exchanged for 23,273,179 shares of Class A common stock, relieving the company of future interest payment obligations on the exchanged debt and extinguishing certain debt covenants.

Sentiment

Score: 4

Explanation: The sentiment is mixed. While the company demonstrated strong revenue and membership growth and took strategic steps to manage its capital structure, it reported significantly wider net losses, operating losses, and Adjusted EBITDA losses compared to the prior year, alongside an increased medical loss ratio. The reaffirmation of guidance suggests these results were anticipated, but the continued losses are a concern.

Positives

• Total revenue increased by approximately 23.2% to $3.0 billion in Q3 2025 from $2.4 billion in Q3 2024.
• Total membership grew by approximately 27.9% to 2,116,904 members as of September 30, 2025, compared to 1,654,284 members in the prior year.
• The SG&A expense ratio improved to 17.5% in Q3 2025 from 19.0% in Q3 2024, reflecting greater fixed cost leverage, lower exchange fee rates, and disciplined cost management.
• The exchange of $187.5 million in convertible senior notes for shares reduces future interest expense and simplifies the balance sheet.
• Debt covenants in the Investment Agreement dated January 27, 2022, were extinguished, and $410 million of 2.25% convertible senior subordinated notes due 2030 ceased to be subordinated to the 2031 Notes.

Negatives

• Net loss attributable to Oscar Health, Inc. widened to $137.5 million in Q3 2025 from $54.6 million in Q3 2024.
• Loss from operations increased to $129.3 million in Q3 2025 from $48.4 million in Q3 2024.
• Adjusted EBITDA loss significantly widened to $101.5 million in Q3 2025 from $11.6 million in Q3 2024.
• The medical loss ratio (MLR) increased to 88.5% in Q3 2025 from 84.6% in Q3 2024, primarily due to a $130 million increase in the net risk adjustment transfer accrual from higher average market morbidity.

Risks

• Ability to execute strategy and manage growth effectively, including integrating strategic acquisitions.
• Ability to retain and expand the member base.
• Ability to accurately estimate incurred medical expenses or effectively manage medical costs and related administrative costs.
• Ability to maintain profitability in the future.
• Unanticipated results of, or changes to, risk adjustment programs or estimates thereof.
• Ability to arrange for quality care delivery and maintain good relations with brokers and providers.
• Evolving federal or state laws or regulations, including changes to the Patient Protection and Affordable Care Act (ACA) and potential renewal or non-renewal of enhanced Advanced Premium Tax Credits (APTCs).
• Ability to comply with ongoing regulatory requirements, including capital reserve and surplus requirements.
• Changes or developments in the health insurance markets in the United States.
• Compliance with laws, regulations, and standards related to handling individual information or consumer protection laws.
• Heightened competition in the markets.
• Ability to utilize quota share reinsurance to meet capital and surplus requirements and protect against downside risk.
• Unfavorable or costly outcomes of lawsuits, audits, investigations, and other third-party claims.
• Incurrence of data security breaches of information and technology systems.
• Ability to attract and retain qualified personnel.
• Ability to detect and prevent material weaknesses or significant control deficiencies in internal controls over financial reporting.
• Adverse publicity or other adverse consequences related to the dual class structure or controlled company status.

Future Outlook

The company reaffirmed its full year 2025 outlook across all metrics. Management is confident in its ability to expand margins and return to profitability in 2026.

Management Comments

• "The individual market is the only source of affordable health coverage for 22 million people who power our economy. Our market serves the small business, service, and farming sectors, and can meet the healthcare needs of 100 million more working people."
• "Oscar is shaping the future of individual healthcare with affordable, innovative plans and a superior member experience. Our disciplined pricing and geographic expansion position us to profitably grow market share, and we are confident in our ability to expand margins and return to profitability in 2026."

Industry Context

Oscar Health positions itself as a leader in the individual health insurance market, serving small businesses, service, and farming sectors. The company aims to address the healthcare needs of a large segment of the working population with affordable, innovative plans and a superior member experience, indicating a focus on market share growth and future profitability within this specific segment.

Comparison to Industry Standards

• The filing does not provide specific comparable companies, projects, or results to assess the company's performance against global benchmarks or industry peers.

Stakeholder Impact

• Shareholders: Experience dilution from the issuance of 23.3 million shares for the convertible notes exchange, but benefit from reduced future interest expense and a simplified balance sheet. Continued losses may impact share price.
• Creditors (2031 Noteholders): Dragoneer exchanged a significant portion of its notes for equity, altering its position from debt holder to equity holder. Other 2031 noteholders may consider similar exchanges. The 2030 noteholders benefit from their notes no longer being subordinated.
• Customers/Members: Continued growth in membership suggests successful market penetration and potentially attractive offerings, aligning with the company's goal of providing affordable and innovative plans.
• Employees: The disciplined cost management and focus on profitability in 2026 could imply ongoing scrutiny of operational expenses, potentially impacting employee-related expenses.

Next Steps

• The company will file its Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2025, with the SEC.
• Dragoneer has until December 14, 2025, to elect to exchange the remaining portion of its 2031 Notes.

Key Dates

Recommendation

The company's Q3 2025 results present a mixed picture. While strong membership and revenue growth, coupled with an improved SG&A expense ratio and strategic debt-to-equity conversion, are positive indicators of operational efficiency and capital management, the significantly wider net and operating losses, along with an increased medical loss ratio, remain a concern. The reaffirmation of full-year guidance suggests these results were within expectations, and the target of profitability in 2026 provides a future catalyst. However, the current financial performance does not warrant a 'buy' given the widening losses, nor a 'sell' given the strategic actions and growth. A 'hold' recommendation is appropriate as investors await further progress towards profitability and the impact of the capital structure changes.

Keywords

Oscar Health, OSCR, Q3 2025, Financial Results, Health Insurance, Medical Loss Ratio, Adjusted EBITDA, Membership Growth, Convertible Notes, Capital Structure, SEC Filing